- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04258618
Cognitive Behavioral Therapy for Insomnia With rTMS
March 3, 2021 updated by: Michael Norred, Medical University of South Carolina
CBT-I Targeting Co-morbid Insomnia in Patients Receiving rTMS for Treatment-Resistant Major Depressive Disorder
Depression and insomnia occur together in a substantial number of patients.
Transcranial magnetic stimulation (TMS) is an effective treatment for depression, but does not help insomnia symptoms in depressed patients.
A form of cognitive behavioral therapy (CBT) has been developed that specifically helps with insomnia (CBT-I).
The study team will give CBT-I to patients who are being treated with TMS for depression, who also have insomnia, to determine if it helps insomnia symptoms.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults aged 18-85 years old
- Patients starting rTMS treatment for MDD
- Co-morbid insomnia as determined by meeting the following criteria: (a) Requiring more than 30 minutes to fall asleep at the beginning of the night or more than 30 minutes of time awake after initially falling asleep for at least 3 nights per week for at least 3 months - - An insomnia severity index score of 15 or more
- Manifested sleep disturbances or associated daytime symptoms causing significant distress or impairment in social, occupational or other areas of functioning
- Reliable access to a computer with internet access.
Exclusion Criteria:
- Obligation to an irregular sleep schedule that prevents the adoption of intervention strategies such as shift workers
- Participants who have received or are receiving CBT-I targeting insomnia in the past, or those who have initiated a new sedative medication, or sedating antidepressant within 2-weeks preceding enrollment
- Comorbid psychiatric disorders, including bipolar disorder, psychotic disorders or depression with psychotic features
- Presence of another untreated sleep disorder such as obstructive sleep apne
- Pregnancy
- Active substance use disorder within the past 3 months
- Use of medications that reduce the seizure threshold including Buproprion, stimulants or augmenting thyroid medications (for those without history of hypothyroid)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CBT-I (Cognitive Behavioral Therapy for Insomnia) with TMS
|
Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI.
This includes weekly, one hour sessions addressing sleep for 6 weeks.
|
Other: rTMS (repetitive Transcranial Magnetic Stimulation)
Subjects will be getting Transcranial Magnetic Stimulation as part of their standard of care.
|
Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment.
This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression.
Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Reported Unanticipated Adverse Events
Time Frame: Baseline through post intervention (6 weeks)
|
Tolerability of CBT-I with TMS determined by patient reported adverse event as assessed by red cap form
|
Baseline through post intervention (6 weeks)
|
Percentage of patients completing CBT-I program
Time Frame: Determined post intervention (6 weeks)
|
Feasibility of implementation of CBT-I as assessed by completion percentage of patients enrolled.
|
Determined post intervention (6 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Epworth Sleepiness Scale
Time Frame: Baseline and post intervention (6 weeks)
|
Assessing pre and post TMS treatment changes of ESS in TMS + CBT-I group vs no CBT-I group.
The scale is scored 0-24 assessing degree of sleepiness.
Cutoff scores are as follows: 0-7:It is unlikely that you are abnormally sleepy.
8-9:You have an average amount of daytime sleepiness; 10-15:You may be excessively sleepy depending on the situation.
You may want to consider seeking medical attention;16-24:You are excessively sleepy and should consider seeking medical attention.
This scale is often used clinically for obstructive sleep apnea, but can be useful to assess daytime impact of insomnia.
|
Baseline and post intervention (6 weeks)
|
Change in Insomnia Severity Index Scale
Time Frame: Baseline through post intervention (6 weeks)
|
Assessing pre and post TMS treatment changes of ISI in TMS + CBT-I group vs no CBT-I group.
This scale is scored 0-28 and is used to assess severity of insomnia with cutoff scores as follows: 0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia;15-21 = Clinical insomnia (moderate severity); 22-28 = Clinical insomnia (severe).
|
Baseline through post intervention (6 weeks)
|
Change in Patient Health Questionnaire - 9
Time Frame: Baseline through post intervention (6 weeks)
|
Assessing pre and post TMS treatment changes of PHQ-9 in TMS + CBT-I group vs no CBT-I group.
This scale is used to assess depression severity.
Cutoff scores are as follows: 0-4: Minimal or none; 5-9: Mild; 10-14: Moderate; 15-19: Moderately severe; 20-27: Severe.
|
Baseline through post intervention (6 weeks)
|
Change in Pittsburgh Sleep Quality Index
Time Frame: Baseline and post intervention (6 weeks)
|
Assessing pre and post TMS treatment changes of PSQI in TMS + CBT-I group vs no CBT-I group.
This scale is a 9-item questionnaire assessing sleep quality.
The score is determined by adding up 7 components, with a score of 5 or greater being considered poor sleep.
|
Baseline and post intervention (6 weeks)
|
Change in Hamilton Rating Scale for Depression 17
Time Frame: Baseline and post intervention (6 weeks)
|
Assessing pre and post TMS treatment changes of HRSD 17 in TMS + CBT-I group vs no CBT-I group.
This is a 17- item scale assessing severity of depression symptoms and is scored out of 58 (8 questions scored out of 5 and 9 questions scored out of 2), with 0-7 considered normal and > 20 considered at least moderate severity.
|
Baseline and post intervention (6 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Michael Norred, MD, Medical University of South Carolina
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 4, 2020
Primary Completion (Actual)
January 31, 2021
Study Completion (Actual)
January 31, 2021
Study Registration Dates
First Submitted
February 4, 2020
First Submitted That Met QC Criteria
February 5, 2020
First Posted (Actual)
February 6, 2020
Study Record Updates
Last Update Posted (Actual)
March 5, 2021
Last Update Submitted That Met QC Criteria
March 3, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00089725
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS
-
VA Office of Research and DevelopmentTerminatedSleep Initiation and Maintenance Disorders | Marijuana AbuseUnited States
-
University of RochesterNational Institute of Nursing Research (NINR); National Institute of Neurological... and other collaboratorsCompleted
-
Johns Hopkins UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedOsteoarthritis | Sleep Initiation and Maintenance DisordersUnited States
-
University of FloridaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
American University of Beirut Medical CenterRecruiting
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)RecruitingChronic Insomnia | Cancer-related Problem/Condition | Cancer-Related SyndromeUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedDepression | InsomniaUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedInflammatory Bowel Diseases | InsomniaUnited States
-
The University of Hong KongKowloon Hospital, Hong KongCompleted
-
CHU de Quebec-Universite LavalCanadian Institutes of Health Research (CIHR)Completed